Cargando…

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series

Patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-PAH-CTD) such as systemic sclerosis (SSc) have a poorer response to treatment and increased mortality compared with patients with idiopathic PAH. Current treatment options for PAH-CTD include prostanoids, ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raina, Amresh, Benza, Raymond L., Farber, Harrison W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841890/ https://www.ncbi.nlm.nih.gov/pubmed/28671485 http://dx.doi.org/10.1177/2045893217721694

Ejemplares similares

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension
por: Verlinden, Nathan J., et al.
Publicado: (2020)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension
por: Joshi, Aditya A., et al.
Publicado: (2018)

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
por: Benza, Raymond L., et al.
Publicado: (2021)

Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat
por: Rahaghi, Franck F., et al.
Publicado: (2022)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
por: García Aguilar, Humberto, et al.
Publicado: (2022)

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
por: Humbert, Marc, et al.
Publicado: (2017)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

Risk assessment in pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2016)

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study
por: Benza, Raymond L., et al.
Publicado: (2017)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review
por: Wesley Milks, Michael, et al.
Publicado: (2021)

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
por: Liu, Yu-Yang, et al.
Publicado: (2023)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling
por: Taran, Irina N., et al.
Publicado: (2018)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
por: Mihalek, Andrew D, et al.
Publicado: (2022)

Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension
por: Kenny, Marianne, et al.
Publicado: (2020)

The Evolution of Risk Assessment in Pulmonary Arterial Hypertension
por: Murthy, Sandhya, et al.
Publicado: (2021)

Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
por: Poch, David S.
Publicado: (2016)

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
por: Liu, Yu-Yang, et al.
Publicado: (2023)

An Unlikely Trio: Profound Anemia, Elevated Lactate, and Riociguat
por: Farmer, Mary Jo S, et al.
Publicado: (2022)

Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
por: Weir, Nargues A., et al.
Publicado: (2018)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension
por: Spreemann, Till, et al.
Publicado: (2017)

Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis
por: Ying, Miaofa, et al.
Publicado: (2021)

Ameliorated nailfold capillary morphology of patients with pulmonary arterial hypertension in systemic sclerosis, treated with riociguat
por: Sugimoto, Tomohiro, et al.
Publicado: (2023)

Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
por: Sulica, Roxana, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o59nhngmkob46anug6u5ia0ge2